MCAS Biology
Comprehensive coverage
This note is a compact reference. For the full wiki-style biochemistry course, start at Mast Cell Education — it covers every concept here in dedicated notes with cross-references.
What Is MCAS
Mast Cell Activation Syndrome — mast cells activate (degranulate) inappropriately. Too easily, too often, or in response to stimuli that shouldn’t trigger them. Distinct from mastocytosis (too many mast cells); MCAS is behavioral dysfunction in normal cell counts.
Diagnosis criteria vary, but generally: recurrent systemic symptoms across multiple organ systems, evidence of mast cell mediator release, and response to mast-cell-targeted treatment. Response to treatment is part of the diagnostic criteria — the treatment is also the diagnostic test.
Mast Cells
Tissue-resident immune cells, dense near blood vessels, nerves, and epithelial surfaces (gut, skin, airways). Sentinels at host-environment interfaces. Loaded with granules containing preformed mediators ready for rapid release. See Mast Cells for full detail.
High-affinity IgE receptors (FcεRI) on surface. Classic trigger: antigen cross-links IgE → receptor clustering → tyrosine kinase signaling → calcium influx → granule fusion → mediator release. See IgE-Mediated Activation. For the many non-IgE triggers, see Non-IgE Activation Pathways.
Degranulation Phases
See Degranulation for the full mechanism including piecemeal vs. full degranulation.
Immediate (seconds–minutes): Preformed mediators — Histamine, Tryptase, Heparin, TNF-α.
Arachidonic Acid cascade (minutes–hours): Membrane phospholipids → Prostaglandins (PGD2) and Leukotrienes (LTC4/D4/E4). Processed by COX Enzymes and 5-LOX respectively.
De novo cytokine synthesis (hours): IL-4, IL-5, IL-13 — longer-tail inflammatory response.
Key Mediators
See Mast Cell Mediators for a comprehensive overview.
| Mediator | Effect |
|---|---|
| Histamine | Vasodilation, permeability, itch, gastric acid, bronchoconstriction |
| Tryptase | Serine protease; diagnostic marker; activates PAR-2 (amplification loop) |
| Heparin | Anticoagulant; explains easy bruising |
| PGD2 | Vasodilation, bronchoconstriction, flushing |
| D4 | Potent bronchoconstrictors, gut motility |
| PAF | Bronchoconstriction, hypotension |
Liberators vs Stabilizers
Liberators (secretagogues): Trigger degranulation without IgE involvement. Direct mast cell activation. Examples: alcohol, NSAIDs (COX-1 inhibition), citrus, fermented foods, shellfish, opioids (via MRGPRX2), temperature extremes, pressure. See Histamine Liberators and Non-IgE Activation Pathways.
Stabilizers: Reduce mast cell reactivity — raise degranulation threshold or inhibit mediator release downstream. See Mast Cell Stabilizers, Cromolyn Sodium, Ketotifen.
Feedback Amplification Loops
Often overlooked — MCAS isn’t linear:
- Tryptase → PAR-2 → more mast cell activation — tryptase activates PAR-2 which feeds back to cause further degranulation
- Histamine → H4 Receptor on mast cells → more degranulation — autocrine loop
- Neurogenic inflammation — mast cells and sensory nerves co-located; substance P and CGRP from nerves activate mast cells; mast cell mediators sensitize nerves. See Small Fiber Neuropathy.
- Gut Dysbiosis → leaky epithelium → more luminal antigen → more activation — chronic low-level activation cycle. See The Gut-Brain-Mast Cell Axis.
Prevalence
The 17% figure (Molderings et al. 2021) is symptom-criteria based on general population surveys — not confirmed diagnoses. Uses the most permissive diagnostic criteria. Actual diagnosed prevalence is orders of magnitude lower, partly because most physicians don’t know how to diagnose it.
Real number is probably between “vastly underdiagnosed” and “17% of humans have this.” The figure likely captures a real population with mast cell dysfunction on a spectrum, not all of whom meet stricter criteria.
Clinically, the label matters less than the mechanism. If mast cells are the problem, the treatment targets are the same regardless of whether the chart says MCAS, fibromyalgia, or idiopathic chronic urticaria. The label matters for prescription access, ruling out mastocytosis, and research/disability infrastructure — not for the biology. See Intervention Targets for the full therapeutic target landscape.